The U.S. Food & Drug Administration (FDA) has approved the New Drug Application for Rockwell Medical Inc.’s Triferic Powder Packet for commercial sale as an iron replacement product to maintain hemoglobin in adult patients with hemodialysis dependent chronic kidney disease.
“The Triferic powder packet is similar to the size of a packet of sugar,” said Robert L. Chioini, chairman and CEO of Rockwell. “It is much smaller and lighter than the current Triferic liquid ampule and it enables us to place three-times greater the number of units in an even smaller carton. This presentation is much more convenient for customers as it reduces storage space and requires fewer reorders to maintain inventory. We expect it to be commercially available shortly.”